Introduction {#S0001}
============

Anaplastic lymphoma kinase (*ALK*) fusions are relatively common in young, non-smoking patients, and approximately 2--7% of patients with lung adenocarcinoma are identified to carry the fusion variants.[@CIT0001],[@CIT0002] Targeted therapies of *ALK* fusions by drugs such as crizotinib, ceritinib, alectinib, and brigatinib, are widely used to treat the *ALK* fusion-positive patients with non-small cell lung cancer (NSCLC).[@CIT0003]--[@CIT0008] Previous studies have demonstrated that the next-generation sequencing (NGS) technology could be utilized to circulating tumor DNA (ctDNA) extracted from patients' peripheral blood to guide their clinical treatments.[@CIT0009]--[@CIT0011]

Here, we report a novel *HPCAL1-ALK* fusion variant in ctDNA was identified in a patient with NSCLC responding to *ALK* inhibitor treatments, using an ultra-deep (20000X) 160-gene panel through the NGS platform (shown in [[Supplementary Materials](http://www.dovepress.com/get_supplementary_file.php?f=252210.docx)]{.ul} and [[Table S1](http://www.dovepress.com/get_supplementary_file.php?f=252210.docx)]{.ul}).

Case Report {#S0002}
===========

The patient was a 53-year-old Chinese male with a smoking history. The timeline of his diagnosis and treatment was shown in [Figure 1A](#F0001){ref-type="fig"} and the detailed description was as follows. In January 2018, the patient started to have symptoms of coughing, shortness of breath, chest pain, back pain and hemoptysis. The initial chest computed tomographic (CT) scan showed an irregular mass shadow with the size of 7x4 cm in the right middle lobe, accompanied by local atelectasis, mediastinal lymphadenopathy and right lower hilar lymph node enlargement of 4x4 cm ([Figure 1B](#F0001){ref-type="fig"}). The single-photon emission computerized tomography (SPECT) imaging of whole-body bone scan revealed abnormal isotopic accumulation in multiple sites and the CT guided lower lung biopsy sample showed moderately differentiated adenocarcinoma. Overall, the patient was newly diagnosed as right lung adenocarcinoma, bone metastasis and T4N2M1 stage IV.Figure 1Clinical course and representative clinical images of the patient with NSCLC.**Notes:** (**A**) Patient's treatment timeline showed the application of different drug treatments. (**B)** CT scan images were taken during baseline of cancer diagnosis, the GP regimen/recombinant human endostatin (Endostar) combinational treatment, and the PP regimen/bevacizumab combinational treatment, respectively. (**C)** CT scan images were taken during oral crizotinib treatment, and oral alectinib treatment, respectively. (**D)** Map of clonal evolution. Two ctDNA samples were collected before and after crizotinib treatment. The different colors represent different gene mutation sites, as measured by NGS platform.**Abbreviations:** NSCLC, non-small cell lung cancer; ctDNA, circulating tumor DNA; NGS, next-generation sequencing.

Starting from February 2018, the patient was given 4 cycles of chemotherapy (GP regimen + recombinant human endostatin (Endostar)), and symptoms of coughing and shortness of breath were significantly relieved after the treatment. The chest CT scan showed a reduced right lung lesion of 3x3 cm, the size of lower hilar lymph node was down to 2.5x2.5 cm and local atelectasis and pericardial effusion were alleviated ([Figure 1B](#F0001){ref-type="fig"}). According to RECIST version 1.1, the efficacy was evaluated as partial response (PR).

However, in late June 2018, the patient again developed coughing, shortness of breath, and lower back pain. The chest CT scan revealed an elevated local atelectasis, large amount of pericardial effusion and bilateral pleural effusion. The patient was given two cycles of chemotherapy (PP regimen + bevacizumab) but improvements were not observed after a thorough re-examination ([Figure 1B](#F0001){ref-type="fig"}). Fiberoptic bronchoscopy was performed in January 2019. The irregular swelling in the middle lobe of the right lung was found to swell and grow into the lumen, resulting in narrowing of the bronchus in the middle lobe of the right lung. The biopsy was pathologically lung adenocarcinoma. CtDNA extracted from the peripheral blood of the patient was sequencing based on the NGS platform, and the result showed a novel in-frame *HPCAL1-ALK* fusion, in which the full kinase domain of *ALK* was retained. The breakpoint was inside intron 1 of *HPCAL1* and intron 19 of *ALK* and the abundance of the fusion gene was 1.87% ([Figure 1D](#F0001){ref-type="fig"}, [2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). Oral crizotinib was administrated to the patient at 250 mg bid. After a month of treatment in February 2019, the chest CT scan displayed a relived atelectasis and diminished hilar lymph node tumor. The efficacy evaluation was PR ([Figure 1C](#F0001){ref-type="fig"}). The patient continued to proceed with the oral crizotinib treatment.Figure 2Identification of the novel *HPCAL1-ALK* fusion.**Notes:** (**A**) Structural illustration showed the *HPCAL1-ALK* fusion variant. (**B)** IGV image showed chimeric reads indicated *HPCAL1-ALK* fusion by NGS platform. (**C)** The representative FISH image showed split red-green or single red dots which indicating *ALK* fusion. Vysis ALK Break Apart Fish Probe Kit and Olympus Model BX51 Fluorescent Microscope were used for FISH detection. (**D)** The representative IHC staining image showed a strong protein expression, using *ALK* D5F3 (Ventana; 300X). **Abbreviations:** IGV, integrative genomics viewer; NGS, next-generation sequencing; FISH, fluorescence in situ hybridization; IHC, immunohistochemical.

In April 2019, the re-examination CT scan revealed that the lesion at the right lung bronchus was almost disappeared, bilateral pleural effusion and pericardial effusion were nearly absorbed, but the tumor at the hilar lymph node was enlarged and the inflammation in the right lower lung was aggravated ([Figure 1C](#F0001){ref-type="fig"}). The *HPCAL1-ALK* fusion variant was then confirmed by fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) in formalin fixed paraffin-embedded (FFPE) tissues ([Figure 2C](#F0002){ref-type="fig"} and [D](#F0002){ref-type="fig"}). In June 2019, symptoms of coughing and shortness of breath were worsened and discomfort in the upper right abdominal was developed. Chest CT scan showed increased right lung lesion of 2x4 cm, atelectasis at the right middle lobe, enlarged right lower hilar lymph node of 3x3 cm, pleural effusion, pericardial effusion and multiple metastases in the liver. The cranial MRI results showed multiple brain metastases, with a maximum lesion of 0.7x0.7 cm ([Figure 1C](#F0001){ref-type="fig"}). At this point, the efficacy was assessed as progressive disease (PD). A second NGS detection in ctDNA was performed and the *HPCAL1-ALK* fusion was identified again at the abundance rate of 0.36% ([Figure 1D](#F0001){ref-type="fig"}). And then oral alectinib was prescribed to the patient at 600 mg bid. Chest CT scan performed in August 2019 showed reduced pleural effusion, relieved atelectasis at the right middle lobe, disappearance of pericardial effusion and inflammation in the right lower lung, and the size of right lung lesion and right lower hilar lymph node was reduced to 2x3 cm and 1.5x1 cm, respectively. Liver metastatic sites were also significantly smaller than before and partially disappeared. The cranial MRI image showed that the brain metastases almost disappeared ([Figure 1C](#F0001){ref-type="fig"}). The efficacy of the treatment was assessed as PR. The patient continued to receive the oral alectinib treatment.

Discussion {#S0003}
==========

In this study, we reported a 53-year-old Chinese male with NSCLC. After the patient's first two lines of chemotherapy failed, a subsequent ctDNA test revealed a novel *HPCAL1-ALK* fusion variant. The patient was then treated with crizotinib for targeted therapy. As crizotinib is a protein kinase inhibitor that binds target kinase pockets by competitively binding ATP,[@CIT0012] the patient's symptoms were markedly relieved for nearly five months. However, the patient relapsed at a later stage and alectinib was used to treat this patient with crizotinib resistance.

Based on literature retrieval of PubMed and Web of Science, the *HPCAL1-ALK* fusion variant we found was not reported. However, we found that patient with the fusion variant responded to both crizotinib and alectinib. Several studies have shown that this *HPCAL1* gene is involved in calcium-dependent regulation of rhodopsin phosphorylation and is related to neuronal signaling in the central nervous system. The protein the gene encodes is a member of the family of neuron-specific calcium-binding proteins that are common in the retina and the brain.[@CIT0013]--[@CIT0015] However, the molecular mechanism and function of the *HPCAL1-ALK* fusion variant remains to be further studied, especially in NSCLC.

Some studies have shown that accurate identification of fusion partners affects treatment selection and plays an important role in prognosis. McLeer-Florin et al found that the clinical efficacy of NSCLC patients with *EML4* (exon 13)*-ALK* (exon 20) and *EML4* (exon 20)-*ALK* (exon 20) variants based on crizotinib treatment was superior to that of patients with *EML*4 (exon 6)-*ALK* (exon 20) variants,[@CIT0016] suggesting that it is of great significance to evaluate the efficacy of crizotinib based on *ALK* variation types. Drilon et al found that based on RET inhibitor therapy, NSCLC patients with the *KIF5B-RET* fusion variant had a statistically significant difference in the objective remission rate when compared with patients with other non- *KIF5B* partners,[@CIT0017] indicating that the accurate detection of the *RET* fusion variant partners is conducive to clinical efficacy evaluation. Li et al found that a novel *TFG-ROS1* fusion variant in an inflammatory myofibroblastic tumor (IMT) patient had a certain response to the treatment of ROS1 inhibitor ceritinib,[@CIT0018] showing that the targeted therapy based on fusion variant can bring clinical benefit to patients.

As the clinical significance of fusion gene detection has been gradually proved, more and more technical methods have been applied to detect fusion variants, including FISH, IHC and NGS. FISH and IHC, as conventional fusion gene detection methods, have certain limitations, mainly because they cannot accurately determine the unknown fusion gene partner and the precise breakpoint. But ctDNA testing based on the NGS platform can reveal more details about the breakpoint structure of fusion genes, making up for the limitations of FISH and IHC.[@CIT0019],[@CIT0020] Furthermore, this approach based on ctDNA testing is feasible in the absence of sufficient samples for tissue genetic testing and can greatly reduce the complexity of molecular work, providing a solution to the evolving actionable targets in NSCLC.[@CIT0021]

To the best of our knowledge, we identified a novel *HPCAL1-ALK* fusion variant in the blood sample of a male patient with NSCLC. The patient firstly received the *ALK* inhibitor crizotinib treatment and efficacy was observed. Alectinib was secondly used after the patient showed resistance to the crizotinib and it has shown effective up to now.

Conclusion {#S0004}
==========

In summary, this is the first report on a novel *HPCAL1-ALK* fusion variant identified in NGS and validated by FISH and IHC. The discovery of this new fusion variant has supplemented the mutational spectrum of *ALK* fusion variants, highlights the need for predictive biomarkers, and provides options for the precise treatment of such patients.
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